Paris - Delayed Quote EUR

Euroapi S.A. (EAPI.PA)

Compare
4.3300 +0.1740 (+4.19%)
At close: September 13 at 5:35 PM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
971,300.0000
1,018,900.0000
980,900.0000
892,800.0000
944,600.0000
--
Cost of Revenue
805,800.0000
854,300.0000
804,000.0000
783,700.0000
854,100.0000
--
Gross Profit
165,600.0000
164,600.0000
176,900.0000
109,100.0000
90,400.0000
--
Operating Expense
162,100.0000
160,900.0000
149,800.0000
107,600.0000
98,800.0000
--
Operating Income
3,500.0000
3,700.0000
27,100.0000
1,500.0000
-8,400.0000
--
Net Non Operating Interest Income Expense
-11,800.0000
-8,400.0000
4,000.0000
-1,900.0000
-900.0000
--
Pretax Income
-296,900.0000
-242,800.0000
3,100.0000
-14,600.0000
-11,800.0000
--
Tax Provision
-9,600.0000
-53,000.0000
18,200.0000
-6,500.0000
-5,500.0000
--
Net Income Common Stockholders
-287,300.0000
-189,700.0000
-15,000.0000
-8,100.0000
-6,300.0000
--
Diluted NI Available to Com Stockholders
-287,300.0000
-189,700.0000
-15,000.0000
-8,100.0000
-6,300.0000
--
Basic EPS
-3.06
-2.02
-0.16
-0.09
-0.07
--
Diluted EPS
-3.06
-2.02
-0.16
-0.09
-0.07
--
Basic Average Shares
94,400.0000
94,200.0000
93,700.0000
94,026.8880
94,026.8880
--
Diluted Average Shares
96,100.0000
95,900.0000
95,000.0000
94,026.8880
94,026.8880
--
Total Operating Income as Reported
-283,700.0000
-234,300.0000
-800.0000
-12,800.0000
-10,800.0000
--
Total Expenses
967,900.0000
1,015,200.0000
953,800.0000
891,300.0000
952,900.0000
--
Net Income from Continuing & Discontinued Operation
-287,300.0000
-189,700.0000
-15,000.0000
-8,100.0000
-6,300.0000
--
Normalized Income
-8,708.9929
-3,105.0247
5,925.0000
2,410.5000
-4,572.0000
--
Interest Income
5,200.0000
2,500.0000
8,200.0000
200.0000
1,000.0000
--
Interest Expense
10,800.0000
10,900.0000
4,200.0000
2,100.0000
1,200.0000
--
Net Interest Income
-11,800.0000
-8,400.0000
4,000.0000
-1,900.0000
-900.0000
--
EBIT
-286,100.0000
-231,900.0000
7,300.0000
-12,500.0000
-10,600.0000
--
EBITDA
12,700.0000
71,000.0000
101,800.0000
63,500.0000
61,600.0000
--
Reconciled Cost of Revenue
805,800.0000
854,300.0000
804,000.0000
783,700.0000
854,100.0000
--
Reconciled Depreciation
298,800.0000
302,900.0000
94,500.0000
76,000.0000
72,200.0000
--
Net Income from Continuing Operation Net Minority Interest
-287,300.0000
-189,700.0000
-15,000.0000
-8,100.0000
-6,300.0000
--
Total Unusual Items Excluding Goodwill
-287,900.0000
-238,700.0000
-27,900.0000
-14,300.0000
-2,400.0000
--
Total Unusual Items
-287,900.0000
-238,700.0000
-27,900.0000
-14,300.0000
-2,400.0000
--
Normalized EBITDA
300,600.0000
309,700.0000
129,700.0000
77,800.0000
64,000.0000
--
Tax Rate for Calcs
0.0000
0.0002
0.0003
0.0003
0.0003
--
Tax Effect of Unusual Items
-9,308.9929
-52,105.0247
-6,975.0000
-3,789.5000
-672.0000
--
12/31/2019 - 5/6/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

IPN.PA Ipsen S.A.
105.70
+0.48%
 
DMP.HM Dermapharm Holding SE
32.55
-2.69%
 
HIK.L Hikma Pharmaceuticals PLC
1,936.00
+0.31%
 
ANCR.L Animalcare Group plc
245.00
0.00%
 
MRK.DE Merck KGaA
168.20
-0.21%
 
2196.HK Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
11.920
+1.19%
 
JUVAF Juva Life Inc.
0.0015
0.00%
 
SDZ.SW Sandoz Group AG
35.22
+0.14%
 
4502.T Takeda Pharmaceutical Company Limited
4,137.00
-2.18%
 
PETQ PetIQ, Inc.
30.68
+0.07%